Anti-CGRP monoclonal antibody therapy for migraine is not associated with early adverse bone effects: a prospective, observational, controlled, cohort study

Background and objectiveCalcitonin gene–related peptide (CGRP) is a key mediator in migraine and a target of recent preventive therapies. Since CGRP is also expressed in bone and involved in skeletal regulation, concerns have been raised regarding potential bone effects of CGRP pathway inhibition. W...

Full description

Bibliographic Details

Published in:	Frontiers in Neurology
Main Authors:	Giulia Mallucci, Chiara Camponovo, Alberto Cordella, Rosaria Sacco, Alessia Bellotti, Alessandro Ceschi, Pierpaolo Trimboli, Claudio Gobbi, Chiara Zecca
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2026-05-01
Subjects:	bone mineral density bone turnover markers calcitonin gene-related peptide migraine monoclonal antibodies
Online Access:	https://www.frontiersin.org/articles/10.3389/fneur.2026.1851653/full